Mode
Text Size
Log in / Sign up
N/A N=125 Randomized Quadruple-blind Treatment

Vitamin D, Insulin Resistance, and Cardiovascular Disease

Vitamin D Deficiency · Insulin Resistance · Type 2 Diabetes Mellitus · Cardiovascular Disease · Hypertension

Enrolled (actual)
125
Serious AEs
0.0%
Results posted
Feb 2020
Primary outcome: Primary: Hypertension (24h Blood Pressure, Central Blood Pressure, and Office BP) — 126.6; 131.1; 79.2; 78.9 mm Hg

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Vitamin D3 (Drug); Placebo (Drug)
Age
Adult, Older Adult · 25+ yrs
Sex
All
Sponsor
Washington University School of Medicine
Primary completion
Jan 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Hypertension (24h Blood Pressure, Central Blood Pressure, and Office BP)
126.6; 131.1; 79.2; 78.9; 127.6; 133.2
SECONDARY
Brachial Artery Reactivity Testing
7.8; 8.6; 8.5; 7.5; 7.8; 7.8
SECONDARY
Macrophage Cholesterol Metabolism
1.01; 0.47
SECONDARY
Serum Calcium
9.1; 9.1; 9.2; 9.1; 9.1; 9.3
SECONDARY
HbA1C
7.0; 7.0; 7.4; 6.9; 7.4; 7.0
SECONDARY
Vitamin D
46.1; 40.1; 37.7; 40.7; 44.5; 42.7
SECONDARY
hsCRP
3.7; 6.0; 3.6; 5.9; 4.2; 6.7
SECONDARY
Fasting Glucose
126.7; 123.3; 137.4; 124.9; 138.4; 128.7
SECONDARY
Urine Calcium to Creatinine Ratio.
69.8; 88.1; 102.3; 114.1; 89.9; 134.5

Summary

In recent years, vitamin D has been shown not only to be important for bone and calcium metabolism but also for homeostasis of critical tissues involved in vascular disease in patients with diabetes. Epidemiological studies indicated the high prevalence of vitamin D deficiency among Type 2 DM patients and suggest an increased risk of cardiovascular disease and hypertension with low vitamin D levels. The objective of this proposal is to evaluate the effects of vitamin D replacement on blood pressure control and vascular disease in vitamin D deficient hypertensive patients with diabetes

Eligibility Criteria

Inclusion Criteria

  • Type 2 diabetes
  • 25 (OH) vitamin D levels 160 or diastolic >100 mmHg
  • High urine calcium or history of recurrent kidney stones
  • Cardiovascular disease
  • Stage 3 or worse chronic kidney disease
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00736632). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search